Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)

Maria Teresa Voso, Pl Zinzani, M Tani, A Pulsoni, M Gobbi, A Perotti, S De Luca, A Fabbri, A Zaccaria, P Fattori, L Guardigni, S Ronconi, Mg Cabras, L Rigacci, A De Renzo, E Marchi, V Stefoni, M Fina, C Pellegrini, G MusuracaE Derenzini, S Pileri, S Fanti, Pp Piccaluga, M. Baccarani

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

69 Citazioni (Scopus)

Abstract

Follicular lymphoma is the most common form of lymphoma in Europe and the USA. In this prospective, single-arm, open-labelled, multicentre non-randomised phase II trial (FLUMIZ [FLUdarabine, MItoxantrone, Zevalin] trial) we aimed to assess the efficacy and safety of fludarabine and mitoxantrone plus radioimmunotherapy in untreated patients with follicular non-Hodgkin lymphoma (NHL).
Lingua originaleEnglish
pagine (da-a)352-358
Numero di pagine7
RivistaLANCET ONCOLOGY
Volume9
DOI
Stato di pubblicazionePubblicato - 2008

Keywords

  • Adult
  • Aged
  • Antibodies, Monoclonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Combined Modality Therapy
  • Disease-Free Survival
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Humans
  • Italy
  • Kaplan-Meier Estimate
  • Lymphoma, Follicular
  • Lymphoma, Non-Hodgkin
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Mitoxantrone
  • Neoplasm Staging
  • Probability
  • Radioimmunotherapy
  • Risk Assessment
  • Survival Analysis
  • Vidarabine
  • Yttrium Radioisotopes

Fingerprint

Entra nei temi di ricerca di 'Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)'. Insieme formano una fingerprint unica.

Cita questo